Gujarat Themis Biosyn Ltd vs Sotac Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Gujarat Themis Biosyn Ltd is ₹ 363.75 as of 30 Apr 15:30 . The P/E Ratio of Gujarat Themis Biosyn Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 4 yearsThe P/E Ratio of Sotac Pharmaceuticals Ltd changed from 31.3 on March 2024 to 16.4 on March 2025 . This represents a CAGR of -27.61% over 2 years The Market Cap of Gujarat Themis Biosyn Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 4 yearsThe Market Cap of Sotac Pharmaceuticals Ltd changed from ₹ 133.71 crore on March 2024 to ₹ 131.22 crore on March 2025 . This represents a CAGR of -0.94% over 2 years The Revenue of Gujarat Themis Biosyn Ltd is ₹ 0 crore as of Jun '24 .The Revenue of Sotac Pharmaceuticals Ltd is ₹ 25.5 crore as of Jun '24 . The EBITDA of Gujarat Themis Biosyn Ltd is ₹ 0 crore as of Jun '24 .The EBITDA of Sotac Pharmaceuticals Ltd is ₹ 2.46 crore as of Jun '24 . The Net Profit of Gujarat Themis Biosyn Ltd is ₹ 0 crore as of Jun '24 .The Net Profit of Sotac Pharmaceuticals Ltd is ₹ 1.35 crore as of Jun '24 . The Dividend Payout of Gujarat Themis Biosyn Ltd changed from 36.62 % on March 2022 to 14.97 % on March 2025 . This represents a CAGR of -20.04% over 4 yearsThe Dividend Payout of Sotac Pharmaceuticals Ltd changed from 13.94 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 years .

About Gujarat Themis Biosyn Ltd

Promoted byJayshree D Patel, Gujarat Themis Biosyn Limited (GTBL) was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985.
It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007. Initially manufacturing the antibiotic, erythromycin, GTBL obtained licences to manufacture bulk drugs like rifampicin, cephalexin, griseofulvin and their formulations in 1990.

About Sotac Pharmaceuticals Ltd

Sotac Pharmaceuticals Limited was originally formed and registered as a Partnership Firm under the Partnership Act, 1932 in the name of 'M/s Sotac Pharmaceuticals', pursuant to a Deed of Partnership dated October 28, 2015.
Thereafter 'M/s.
Sotac Pharmaceuticals' was converted from Partnership Firm to a Private Limited Company in the name of 'Sotac Pharmaceuticals Private Limited' dated December 18, 2015 from the Assistant Registrar of Companies, Gujarat.
Later on, Company converted into a Public Limited Company and the name of Company was changed to 'Sotac Pharmaceuticals Limited' dated November 22, 2022 issued by Registrar of Companies, Ahmedabad. The Company is a part of SOTAC Group, based at Gujarat and is engaged in manufacturing of pharmaceutical products for different marketers on loan license or contract manufacturing basis.

FAQs for the comparison of Gujarat Themis Biosyn Ltd and Sotac Pharmaceuticals Ltd

Which company has a larger market capitalization, Gujarat Themis Biosyn Ltd or Sotac Pharmaceuticals Ltd?

Market cap of Gujarat Themis Biosyn Ltd is 3,963 Cr while Market cap of Sotac Pharmaceuticals Ltd is 129 Cr

What are the key factors driving the stock performance of Gujarat Themis Biosyn Ltd and Sotac Pharmaceuticals Ltd?

The stock performance of Gujarat Themis Biosyn Ltd and Sotac Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Gujarat Themis Biosyn Ltd and Sotac Pharmaceuticals Ltd?

As of May 4, 2026, the Gujarat Themis Biosyn Ltd stock price is INR ₹363.75. On the other hand, Sotac Pharmaceuticals Ltd stock price is INR ₹117.0.

How do dividend payouts of Gujarat Themis Biosyn Ltd and Sotac Pharmaceuticals Ltd compare?

To compare the dividend payouts of Gujarat Themis Biosyn Ltd and Sotac Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.